PMID- 28314294
OWN - NLM
STAT- MEDLINE
DCOM- 20170411
LR  - 20170411
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 3
DP  - 2017 Mar
TI  - Mismatch Repair Protein Deficiency Is a Risk Factor for Aberrant Expression of 
      HLA Class I Molecules: A Putative "Adaptive Immune Escape" Phenomenon.
PG  - 1289-1295
AB  - Accumulating evidence indicates that immune checkpoint inhibition-mediated cancer 
      immunotherapies greatly improve the prognosis of certain types of cancer. This 
      approach is now becoming a standard therapy, joining surgery, radiotherapy, and 
      chemotherapy. Because the costs of antibody drugs are now a socioeconomic burden 
      in many countries, an urgent need in cancer immunotherapy is the identification 
      of relevant biomarkers that can predict therapy efficacy. Recent studies have 
      reported that colorectal adenocarcinoma with hereditary or sporadic deficiency in 
      mismatch repair (MMR) proteins has high antigenicity and that detection of these 
      proteins could be a promising way to estimate clinical response. In this study of 
      135 patients with colorectal cancer, we used immunohistochemistry to investigate 
      the correlation between deficiency in MMR proteins and expression of human 
      leukocyte antigen (HLA) class I molecules, a prerequisite of cytotoxic 
      T-cell-based immunotherapy. Interestingly, MMR protein deficiency was an 
      independent risk factor for the impaired expression of HLA class I molecules 
      (odds ratio (OR)=10.44, 95% confidence interval (CI)=3.15-34.62, p<0.001), 
      suggesting the existence of a putative entity that we have named "adaptive immune 
      escape". Moreover, our results might provide a potential novel biomarker for the 
      selection of patients who would respond to cancer immunotherapies. At the same 
      time, the results suggest that we have to overcome the impaired expression of HLA 
      class I molecules to further improve the cure rate of cancer immunotherapies.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kubo, Terufumi
AU  - Kubo T
AD  - Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, 
      Japan kuboteru@sapmed.ac.jp hirohash@sapmed.ac.jp.
FAU - Hirohashi, Yoshihiko
AU  - Hirohashi Y
AD  - Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, 
      Japan kuboteru@sapmed.ac.jp hirohash@sapmed.ac.jp.
FAU - Matsuo, Kazuhiko
AU  - Matsuo K
AD  - Sapporo Clinical Laboratory Inc., Sapporo, Japan.
FAU - Sonoda, Tomoko
AU  - Sonoda T
AD  - Department of Public Health, Sapporo Medical University, School of Medicine, 
      Sapporo, Japan.
FAU - Sakamoto, Hiroki
AU  - Sakamoto H
AD  - Sapporo Clinical Laboratory Inc., Sapporo, Japan.
FAU - Furumura, Kiyoshi
AU  - Furumura K
AD  - Sapporo Clinical Laboratory Inc., Sapporo, Japan.
FAU - Tsukahara, Tomohide
AU  - Tsukahara T
AD  - Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, 
      Japan.
FAU - Kanaseki, Takayuki
AU  - Kanaseki T
AD  - Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, 
      Japan.
FAU - Nakatsugawa, Munehide
AU  - Nakatsugawa M
AD  - Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, 
      Japan.
FAU - Hirano, Hiroshi
AU  - Hirano H
AD  - Department of Surgical Pathology, Sapporo Medical University, School of Medicine, 
      Sapporo, Japan.
FAU - Furuhata, Tomohisa
AU  - Furuhata T
AD  - Department of Surgical Oncology and Science, Sapporo Medical University, School 
      of Medicine, Sapporo, Japan.
FAU - Takemasa, Ichiro
AU  - Takemasa I
AD  - Department of Surgical Oncology and Science, Sapporo Medical University, School 
      of Medicine, Sapporo, Japan.
FAU - Hasegawa, Tadashi
AU  - Hasegawa T
AD  - Department of Surgical Pathology, Sapporo Medical University, School of Medicine, 
      Sapporo, Japan.
FAU - Torigoe, Toshihiko
AU  - Torigoe T
AD  - Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, 
      Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adenocarcinoma/*genetics/immunology/therapy
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Neoplasm/chemistry
MH  - Biomarkers, Tumor/metabolism
MH  - Child
MH  - Child, Preschool
MH  - Colonic Neoplasms/*genetics/immunology/therapy
MH  - DNA Mismatch Repair
MH  - Female
MH  - Histocompatibility Antigens Class I/*metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - Immunotherapy
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Risk Factors
MH  - *Tumor Escape
MH  - Young Adult
OTO - NOTNLM
OT  - Adenocarcinoma of the colon
OT  - HLA class I molecules
OT  - cancer immunotherapy
OT  - immune escape
OT  - mismatch repair proteins
EDAT- 2017/03/21 06:00
MHDA- 2017/04/12 06:00
CRDT- 2017/03/19 06:00
PHST- 2017/01/12 00:00 [received]
PHST- 2017/02/22 00:00 [revised]
PHST- 2017/02/24 00:00 [accepted]
PHST- 2017/03/19 06:00 [entrez]
PHST- 2017/03/21 06:00 [pubmed]
PHST- 2017/04/12 06:00 [medline]
AID - 37/3/1289 [pii]
AID - 10.21873/anticanres.11446 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 Mar;37(3):1289-1295. doi: 10.21873/anticanres.11446.